Deucravacitinib (Sotyktu) demonstrated efficacy in treating patients with active psoriatic arthritis (PsA), achieving higher American College of Rheumatology (ACR) 20 response rates (ie, ≥ 20% improvement in disease signs and symptoms) than placebo at week 16, with a consistent overall safety profile.

"These results are particularly encouraging because they support the potential for Sotyktu to impact both joint and skin symptoms, as well as patient-reported quality of life outcomes," Philip Mease, MD, director of rheumatology research at Swedish Medical Center/Providence St. Joseph Health and clinical professor at the University of Washington School of Medicine, Seattle, said in a news release.

This study was conducted by Bristol Myers Squibb.

The press release announcing the trial's results did not discuss any limitations.

This study was sponsored by Bristol Myers Squibb.